Investor Relations

Our Mission

To create a new generation of cell and gene therapies with dynamic control over therapeutic activity, opening new possibilities for patients with difficult-to-treat diseases.

Founded on Smart Science

Senti Bio is a biotechnology company pioneering a new generation of cell and gene therapies with dynamic controls designed to modulate therapeutic activity after administration for patients with difficult-to-treat diseases. Our proprietary Regulator Dial™ technology is designed to enable precise control of therapeutic gene expression using oral medications, with the potential to improve safety and optimize treatment effects. Through research collaborations, we are applying this technology to gene therapy for Rett syndrome and armored tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, two areas of significant unmet need. These research-stage programs seek to address the fundamental challenge of controlling how and when powerful genetic medicines act inside the body.

Driven by Strong Leadership

Senti Bio is led by seasoned professionals with a passion for advancing life-changing therapies.

Co-Founder and Chief Executive Officer, Dr. Tim Lu, is a pioneer in synthetic biology and has co-founded multiple therapeutics platform companies including Synlogic, Tango Therapeutics, Eligo Bioscience, BiomX and Engine Biosciences. Chief Financial Officer, Jay Cross, is a proven financial leader with extensive experience as a healthcare investment banker on Wall Street. President, Head of Research & Development and Chief Medical Officer, Dr. Kanya Rajangam, is an experienced biotechnology executive with an extensive track record of successfully obtaining commercial approval for multipe products globally across multiple modalities including allogeneic cell therapies.